Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionGlobeNewsWire • 10/31/24
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/14/24
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024GlobeNewsWire • 08/07/24
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramGlobeNewsWire • 06/24/24
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.GlobeNewsWire • 06/13/24
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024GlobeNewsWire • 05/16/24
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/09/24
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024GlobeNewsWire • 05/02/24
Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/27/24
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationGlobeNewsWire • 03/25/24
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseGlobeNewsWire • 03/22/24
Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsGlobeNewsWire • 03/22/24
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisGlobeNewsWire • 02/20/24
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesGlobeNewsWire • 12/27/23
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAGlobeNewsWire • 12/21/23
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelGlobeNewsWire • 11/07/23